Prostate Cancer International is
for 2011 by Great NonProfits
There’s a new article in the radiation therapy literature suggesting a direct correlation between prostate volume and risk for severe, acute, genitourinary toxicity when prostate cancer patients with large-volume prostates are treated with intensity-modulated radiation therapy (IMRT).
Filed under: Management, Treatment | Tagged: genitourinary toxicity, IMRT, risk, volume | Leave a Comment »
There have been strong suggestions over the years (at least from some physician groups) that the combination of brachytherapy with external beam radiotherapy (EBRT) was associated with superior outcomes compared to the use of EBRT alone in treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: brachytherapy, HDR, high-dose-rate, IMRT, intensity-modulated radiation therapy, outcome | 4 Comments »
The relative merits of proton beam radiotherapy (PBRT) and the more commonly available intensity-modulated radiotherapy (IMRT) as forms of external beam radiation for prostate cancer are much debated … with minimal supportive evidence on either side of the debate because no comparative trial has ever been carried out.
Filed under: Management, Treatment | Tagged: cancer, IMRT, intensity-modulated, PBRT, proton beam, radiation, second, therapy | 3 Comments »
Todays news reports adddress: Surgeon and hospital volume and outcomes to radical prostatectomy Adverse events associated with the use of hypofractionated, dose-escalated, IMRT Quality of sexual function after external beam radiation therapy Percentage of positive biopsy cores and response to first-line hormone therapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, core, EBRT, external beam radiation therapy, hormone therapy, hospital, hypofractionated, IMRT, radical prostatectomy, sexual function, surgeon, volume | Leave a Comment »
Today’s news reports cover items on: Gene expression and prostate cancer progression Risk of complications from in-office prostate biopsy Post-RALP voiding function Urinary toxicities after IMRT-SIB Drugs in development for CRPC
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a Comment »
Today’s news reports address: Prevalence of comorbidities in black and white patients PSA screening and the criteria for biopsy Screening and management of men > 65 years of age Genitourinary toxicity of intensity modulated radiation therapy (IMRT)
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: comorbidity, genitourinary toxicity, IMRT, race, risk, screening | Leave a Comment »
Our third report today covers such topics as: A positive biopsy risk nomogram for men in New Zealand A review of current trends and priorities in surgical technique for radical prostatectomy A review of the potential of functional MRI-based systems for the diagnosis of prostate cancer Demonstration of a relationship between circulating tumor cells and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biopsy, blood, circulating tumor cells, CTCs, Diagnosis, DNA, functional, IMRT, MRI, New Zealand, nomogram, radical prostatectomy, risk, technique, treatment planning | Leave a Comment »
Today’s news deals with such items as: Toxicities associated with hypofractionated, intensity-modulated radiation therapy Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer A Spanish review of photodynamic therapy A proposed mechanism of action for the investigational drug Apoptone™ (HE3235)
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: Apoptone, cystoprostatectomy, HE3235, hypofractionated, IMRT, photodynamic therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site